Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

APF530

Known as: APF-530 
A controlled-release formulation of a biodegradable poly(ortho ester) polymer, encapsulating the indazole derivative granisetron, with antiemetic… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
e20518 Background: Up to 30% of patients continue to have chemotherapy-induced nausea and vomiting (CINV) despite use of… Expand
Is this relevant?
2016
2016
AIM APF530, extended-release granisetron, provides sustained release for ≥5 days for acute- and delayed-phase chemotherapy… Expand
  • table 1
  • figure 2
  • table 2
  • figure 3
  • table 4
Is this relevant?
2016
2016
BackgroundAPF530 provides controlled, sustained-release granisetron for preventing acute (0–24 h) and delayed (24–120 h… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
Is this relevant?
2015
2015
BACKGROUND A phase 3 trial in patients with cancer who received chemotherapy has shown that subcutaneous (SC) APF530, a sustained… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • table 2
Is this relevant?
2015
2015
BACKGROUND APF530 is a novel sustained-release formulation of granisetron. In a Phase III trial, APF530 500 mg was noninferior to… Expand
Is this relevant?
2015
2015
Background Despite advances with new therapies, a significant proportion of patients (>30%) suffer delayed-onset chemotherapy… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
2014
2014
PurposeSubcutaneous APF530 provides controlled sustained release of granisetron to prevent acute (0–24 h) and delayed (24–120 h… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 3
Is this relevant?
2014
2014
Granisetron and other 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists are first-line agents for preventing chemotherapy… Expand
  • figure 1
  • figure 3
  • table 1
  • table 2
  • table 3
Is this relevant?
2014
2014
Background Regulatory concern about potential QT-interval prolongation by serotonin-receptor antagonist antiemetics prompted… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
2009
2009
9627 Background: APF530 is a polymeric formulation of granisetron providing sustained drug release over 5 days. Two doses (5 and… Expand
Is this relevant?